Articles Tagged With:
-
Nerandomilast Tablets (Jascayd)
The U.S. Food and Drug Administration has approved nerandomilast for the treatment of idiopathic pulmonary fibrosis (IPF). It is the first preferential inhibitor of phosphodiesterase 4B (PDE4B).
-
COVID-19 Vaccine Receipt Was Associated with Better Clinical Outcomes in U.S. Veterans
An observational study from the Department of Veterans Affairs found that individuals who received the 2024-2025 COVID-19 vaccine and the influenza vaccine on the same day had fewer emergency department visits, COVID-19-associated hospitalizations, and deaths related to COVID-19 compared to a group that only received the influenza vaccine.
-
Carotid Artery Stenting: The New Treatment Standard for Asymptomatic Carotid Stenosis?
CREST-2 demonstrates that, in asymptomatic carotid stenosis, carotid artery stenting modestly reduced four-year stroke risk compared with intensive medical management, whereas carotid endarterectomy did not.
-
Vertigo and Altered Postural Perception: Overlapping Symptoms, Distinct Mechanisms
Two distinct vestibular disorders, persistent postural-perceptual dizziness (PPPD) and vestibular migraine (VM), both involve vertigo as a primary symptom. Nearly half of chronic migraine patients also experience vertigo, especially those with aura and allodynia. Since PPPD is seen as a functional maladaptation and VM is associated with cortical hyperexcitability, treatment for vertigo in these two conditions should be tailored to their unique pathophysiological mechanisms.
-
Who Needs Antithrombotic Therapy After Atrial Fibrillation Ablation?
An international trial of rivaroxaban vs. low-dose aspirin started one year or more after successful atrial fibrillation catheter ablation has shown no significant differences in a composite outcome of stroke, systemic embolism, or covert cerebral emboli determined by head magnetic resonance imaging and no differences in major bleeding but shows an increase in clinically relevant minor bleeding with rivaroxaban.
-
A Potential Treatment for Progressive Multifocal Leukoencephalopathy
Fingolimod-associated progressive multifocal leukoencephalopathy in a 67-year-old woman with secondary progressive multiple sclerosis (MS) was treated off-label with tenofovir alafenamide fumarate (TAF), resulting in rapid radiologic improvement and clearance of John Cunningham virus (JCV) from cerebrospinal fluid. Although MS activity emerged after fingolimod withdrawal, TAF was well tolerated and the close temporal association with JCV clearance suggests a potential antiviral effect warranting further study.
-
Total Steps vs. How You Get Them and the Risk of Cardiovascular Events
In a large U.K. Biobank study of subjects who performed a one-week determination of steps/day, those who achieved < 8,000 steps/day were categorized by the duration of their step acquisition periods and were followed for a mean of eight years. All-cause mortality and the development of cardiovascular disease (CVD) were greater in those with short step acquisition periods (< 5 minutes) as compared to those with longer periods (> 15 minutes). Thus, longer step acquisition bouts are more effective in reducing mortality and CVD in those with less-than-ideal total daily step counts.
-
The IMPACT Tool Helps Guide Management of Incidental Meningiomas
In a large international, multicenter, retrospective cohort, the imaging-based IMPACT tool accurately predicted progression risk of incidental meningiomas and effectively stratified patients into low-, medium-, and high-risk groups at initial diagnosis.
-
A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus
In this randomized, double-blind, placebo-controlled trial, investigators demonstrated that ventriculoperitoneal shunt surgery produces a clinically meaningful improvement in gait (but not in cognition or urinary symptoms) at three months in carefully selected patients with idiopathic normal-pressure hydrocephalus.
-
Nursing Claims More Severe, Defense More Expensive
Claims involving nursing care are becoming more severe, with treatment or care allegations remaining the top concern, according to the Nurse Professional Liability Claim Report, 5th edition from Nurses Service Organization (NSO) in Fort Washington, PA.